Your molecular genetic test system for the identification of Clostridium difficile from stool and culture samples and differentiation of non-pathogenic, virulent and hypervirulent strains including ribotype 027
Clostridium (C.) difficile has been known for 30 years as common cause of antibiotic-associated diarrhea. Whereas approximately 5% of healthy adults are asymptomatic intestinal carrier of C. difficile, the prevalence in hospitalized patients is much higher. Risk factors for developing C. difficile-associated diarrhea (CDAD) are previous antibiotic drug therapy, age and prolonged stay in a healthcare setting. 1% of hospitalized patients previously treated with antibiotics develop CDAD.
During the past decade, incidence rates of CDAD and severity of the disease have increased noticeably worldwide. This increase has been associated with the emergence of a new hypervirulent strain which is referred to as ribotype 027, toxinotype III and PFGE NAP1. Ribotype 027 strains are causing more severe clinical courses, increased mortality and recurrent infections. The ribotype 027 strains have certain characteristics which enable a differentiation from other ribotypes. Thus, these strains produce toxin A and B as well as a binary toxin. In addition, they contain an 18-base pair deletion and a deletion at 117 of the tcdC gene and are resistant to moxifloxacin and erythromycin.
Our test system GenoType CDiff permits the simultaneous molecular genetic detection of C. difficile and ribotype 027 from stool and culture samples and rectal smears. Furthermore, GenoType CDiff allows the differentiation between non-pathogenic, virulent and hypervirulent C. difficile strains. The accurate and rapid diagnosis of C. difficile-associated diarrhea is the basis of a successful therapy. The early detection of cases and possible outbreaks is crucial in order to initiate a specific therapy and implement an effective infection control. The identification of the hypervirulent ribotype 027 which indicates severe CDAD is especially important.
Your benefits with GenoType CDiff
- Efficient diagnostics: the diagnostic output of the GenoType CDiff combines the results of several different methods in one single test system. It enables the simultaneous identification of C. difficile, toxin A, toxin B, binary toxin, deletions in the regulatory gene tcdC and resistance to moxifloxacin. Thus, C. difficile can be detected in short time and its pathogenicity and virulence can be reliably determined.
- Saving of time: direct from stool samples, you will receive a valid result with detailed information about the pathogen within only 5 hours. This allows for effective therapy to be started and infection control procedures implemented to monitor and control the spread of the pathogen.
- User-friendly: the DNA•STRIP technology allows both manual and automated processing. The implementation is cost-efficient and can be easily established in your lab.
- Cost-efficient: only minimal equipment is needed which enables even smaller laboratories an easy and cost-effective implementation.
At a glance
Molecular genetic detection system for Clostridium difficile and ribotype 027. Differentiation between non-pathogenic, virulent and hypervirulent C. difficile strains
stool and culture samples, rectal smears
Stool samples: QIAamp DNA Stool Mini Kit (Qiagen) or GXT Stool Extraction Kit (with GenoXtract)
Culture samples: Quick protocol (for further information please refer to the manual)
12 tests No. 319
96 tests No. 31996